Loss of Heterozygosity at Chromosome 16q Is a Negative Prognostic Factor in Korean Pediatric Patients with Favorable Histology Wilms Tumor: A Report of the Korean Pediatric Hematology Oncology Group (K-PHOG)
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose Loss of heterozygosity (LOH) at chromosomes 1p and 16q is a poor prognostic factor in favorable histology Wilms tumor (FHWT). This study investigated the prevalence of LOH at 1p and 16q and evaluated its prognostic value in Korean children with FHWT. Materials and Methods We analyzed 101 FHWT patients who were diagnosed between 1996 and 2016 in Korean Society of Pediatric Hematology Oncology Group hospitals. Using paraffin-embedded kidney tissue samples sent from each center, we reviewed LOH at 1p and 16q in each patient and assessed the prognostic value of LOH status for clinical parameters affecting event-free survival (EFS). Results Of the 101 patients, 12 (11.9%) experienced recurrence; the 3-year EFS was 87.6%. LOH at 1p or 16q was detected in 19 patients (18.8%), with five having LOH at both 1q and 16q. The frequency of LOH at 1p was higher among younger patients (p=0.049), but there was no difference in LOH prevalence according to tumor stage. In the multivariate analysis, LOH at 16q was a significant negative prognostic factor affecting EFS (3-year EFS, 73.7% vs. 91.1%; hazard ratio, 3.95; p=0.037), whereas LOH at 1p was not (p=0.786). Conclusion LOH at 16q was a significant negative prognostic factor affecting outcome in Korean pediatric FHWT patients. Due to the small sample size of this study, large-scale multicenter trials are warranted to investigate the prognostic value of LOH at 1p and 16q in Korean children with FHWT.
Abstract
Purpose Loss of heterozygosity (LOH) at chromosomes 1p and 16q is a poor prognostic factor in favorable histology Wilms tumor (FHWT). This study investigated the prevalence of LOH at 1p and 16q and evaluated its prognostic value in Korean children with FHWT. Materials and Methods We analyzed 101 FHWT patients who were diagnosed between 1996 and 2016 in Korean Society of Pediatric Hematology Oncology Group hospitals. Using paraffin-embedded kidney tissue samples sent from each center, we reviewed LOH at 1p and 16q in each patient and assessed the prognostic value of LOH status for clinical parameters affecting event-free survival (EFS). Results Of the 101 patients, 12 (11.9%) experienced recurrence; the 3-year EFS was 87.6%. LOH at 1p or 16q was detected in 19 patients (18.8%), with five having LOH at both 1q and 16q. The frequency of LOH at 1p was higher among younger patients (p=0.049), but there was no difference in LOH prevalence according to tumor stage. In the multivariate analysis, LOH at 16q was a significant negative prognostic factor affecting EFS (3-year EFS, 73.7% vs. 91.1%; hazard ratio, 3.95; p=0.037), whereas LOH at 1p was not (p=0.786). Conclusion LOH at 16q was a significant negative prognostic factor affecting outcome in Korean pediatric FHWT patients. Due to the small sample size of this study, large-scale multicenter trials are warranted to investigate the prognostic value of LOH at 1p and 16q in Korean children with FHWT.
참고문헌 (16)
- Bu Q, "Association between loss of heterozygosity of chromosome 16q and survival in Wilms' tumor : a meta-analysis", Pathol Res Pract, 214, pp.1772~1777 (2018)
- Kim DH, "Effect of preoperative chemotherapy on outcome of Wilms tumor", Clin Pediatr Hematol Oncol, 18, pp.103~108 (2011)
- Green DM, "The evolution of treatment for Wilms tumor", J Pediatr Surg, 48, pp.14~19 (2013)
- Fernandez CV, "Outcome and prognostic factors in stage III favorable-histology Wilms tumor : a report from the Children's Oncology Group Study AREN0532", J Clin Oncol, 36, pp.254~261 (2018)
- Dome JS, "Risk stratification for Wilms tumor: current approach and future directions", Am Soc Clin Oncol Educ Book, pp.215~223 (2014)
- Grundy PE, "Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor : a report from the National Wilms Tumor Study Group", J Clin Oncol, 23, pp.7312~7321 (2005)
- Skotnicka-Klonowicz G, "16q heterozygosity loss in Wilms' tumour in children and its clinical importance", Eur J Surg Oncol, 26, pp.61~66 (2000)
- Loke BN, "Clinical, pathological and loss of heterozygosity differences in Wilms tumors between Asian and non-Asian children", Int J Cancer, 144, pp.1234~1242 (2019)
- Cone EB, "Biomarkers for Wilms tumor : a systematic review", J Urol, 196, pp.1530~1535 (2016)
- Grundy PE, "Loss of heterozygosity for chromosomes 16q and 1p in Wilms' tumors predicts an adverse outcome", Cancer Res, 54, pp.2331~2333 (1994)
- Messahel B, "Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials : a Children's Cancer and Leukaemia Group(CCLG)Study", Eur J Cancer, 45, pp.819~826 (2009)
- Fawzy M, "Profiling loss of heterozygosity patterns in a cohort of favorable histology nephroblastoma Egyptian patients : what is consistent with the rest of the world", Pediatr Hematol Oncol, 32, pp.548~556 (2015)
- Spreafico F, "Loss of heterozygosity analysis at different chromosome regions in Wilms tumor confirms 1p allelic loss as a marker of worse prognosis : a study from the Italian Association of Pediatric Hematology and Oncology", J Urol, 189, pp.260~266 (2013)
- Green DM, "Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor : a report from the National Wilms' Tumor Study Group", J Clin Oncol, 16, pp.3744~3751 (1998)
- Green DM, "Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor : a report from the National Wilms' Tumor Study Group", J Clin Oncol, 16, pp.237~245 (1998)
- Dix DB, "Treatment of stage IV favorable histology Wilms tumor with lung metastases : a report from the Children's Oncology Group AREN0533 Study", J Clin Oncol, 36, pp.1564~1570 (2018)